Fig 2: Intracellular localization of GPR30 in ovarian cancer cell line SKOV-3. (a) Nuclear GPR30 in pre-treated SKOV-3 cells. (b) Cytoplasmic GPR30 in pre-treated SKOV-3 cells.Each figure is in four parts. Part 1 (top left) shows the blue fluorescence resulting from 4',6-diamidino-2-phenylindole (DAPI) labelling suggesting nuclear binding; Part 2 (top right) shows the green fluorescence resulting from Alexa-488 labelling identifying GPR30 receptors; Part 3 (bottom left) show the SKOV-3 cells without fluorescence; Part 4 (bottom right) shows the integrated picture with DAPI and Alxea-488 fluorescence.

Fig 3: Survival of patients with high-grade ovarian-cancer by nuclear GPR30 status.